QCLS

QCLS is not an operating business you can underwrite on numbers — it's a pre-revenue concept stock wearing a diagnostics-industry code. The only revenue figure SEC XBRL surfaces is $1.58M from FY2019; there is no reported revenue for FY2021–FY2025, so the headline 19.2x P/S is calculated against seven-year-old sales from a business the company has since abandoned. Management explicitly states in the 10-K risk factors that it 'recently shifted our business strategy from pharmaceutical development to laser-based computing for blockchain and high-performance computing,' a qc-LPU100 prototype it admits it 'may not successfully develop, validate or commercialize,' and which depends entirely on a licensing partnership with a single third party (LightSolver Ltd.). This is a speculative technology bet layered on top of stranded legacy pharma assets (Isomyosamine, Supera-CBD), not a diagnostics franchise.

The balance sheet screams distress. The company holds just $987K of cash against operating cash burn of -$9.07M — barely five weeks of runway — and the filing leads with the plainest possible warning: 'We expect that we will need to raise additional capital to fund our operations in order to continue as a going concern.' A -$144M accumulated deficit, five straight years of losses (-$29.9M, -$15.2M, -$4.0M, -$23.4M, -$11.6M), and a -737% net margin confirm this is a serial capital-consumer. The 22.5% drop in share count points to a reverse split, and management flags dilution and Nasdaq continued-listing risk directly — the near-certain equity raise will come at whatever price the market forces.